blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3795160

EP3795160 - RECOMBINANT ONCOLYTIC NEWCASTLE DISEASE VIRUSES WITH INCREASED ACTIVITY [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  03.09.2021
Database last updated on 08.06.2024
FormerThe application has been published
Status updated on  19.02.2021
Most recent event   Tooltip11.02.2022Interruptionpublished on 16.03.2022  [2022/11]
Applicant(s)For all designated states
Thaller, Arno
Benzing 6
91801 Markt Berolzheim / DE
[2021/12]
Inventor(s)01 / see applicant
...
 [2021/12]
Representative(s)Becker Kurig & Partner Patentanwälte mbB
Bavariastraße 7
80336 München / DE
[N/P]
Former [2021/12]Becker & Kurig Partnerschaft Patentanwälte PartmbB
Bavariastrasse 7
80336 München / DE
Application number, filing date19198308.919.09.2019
[2021/12]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3795160
Date:24.03.2021
Language:EN
[2021/12]
Search report(s)(Supplementary) European search report - dispatched on:EP31.03.2020
ClassificationIPC:A61K35/768, A61K39/395, C07K14/125, C07K16/22, C07K16/28, C12N7/00, C12N7/02, C12N15/86
[2021/12]
CPC:
C07K14/005 (EP,US); C12N15/86 (EP,US); A61K35/768 (EP,US);
A61K39/0011 (EP,US); A61K39/3955 (EP); A61P35/00 (US);
C07K16/22 (EP,US); C07K16/2827 (EP,US); C12N7/00 (EP,US);
C12N7/025 (EP); A61K2039/5256 (EP,US); A61K2039/585 (EP,US);
C12N2760/18121 (EP,US); C12N2760/18122 (EP,US); C12N2760/18132 (EP,US);
C12N2760/18142 (US); C12N2760/18143 (EP); C12N2760/18152 (EP,US);
C12N2760/18171 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/40]
Former [2021/12]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:REKOMBINANTE ONKOLYTISCHE NEWCASTLE-KRANKHEITSVIREN MIT ERHÖHTER AKTIVITÄT[2021/12]
English:RECOMBINANT ONCOLYTIC NEWCASTLE DISEASE VIRUSES WITH INCREASED ACTIVITY[2021/12]
French:VIRUS ONCOLYTIQUES RECOMBINANTS DE LA MALADIE DE NEWCASTLE À ACTIVITÉ ACCRUE[2021/12]
Examination procedure26.08.2021Amendment by applicant (claims and/or description)
26.08.2021Examination requested  [2021/40]
26.08.2021Date on which the examining division has become responsible
Fees paidRenewal fee
28.09.2021Renewal fee patent year 03
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Stay/Interruption04.02.2022Interruption of proceedings. Reason: applicant has died[2022/11]
Documents cited:Search[A]WO2006050984  (SCHERING AG [DE], et al) [A] 1-16 * examples 1-12 *;
 [A]WO2018209194  (ICAHN SCHOOL MED MOUNT SINAI [US], et al) [A] 1-16 * claim 1 *;
 [A]CN109627336  (NANJING ANGKELI MEDICINE TECH INNOVATION RESEARCH INSTITUTE CO LTD) [A] 1-16 * claims 1-6 *;
 [A]  - RUI Z ET AL, "Phylogenetic characterization of Newcastle disease virus isolated in the mainland of China during 20012009", VETERINARY MICROBIOLOGY, ELSEVIER BV, NL, vol. 141, no. 3-4, doi:10.1016/J.VETMIC.2009.09.020, ISSN 0378-1135, (20100324), pages 246 - 257, (20090925), XP026925889 [A] 1-16 * Strain KQ/Liaoning/06 in Table 3 *

DOI:   http://dx.doi.org/10.1016/j.vetmic.2009.09.020
 [A]  - R BEIER ET AL, "Isolation of more potent oncolytic paramyxovirus by bioselection", GENE THERAPY, GB, (20120223), vol. 20, no. 1, doi:10.1038/gt.2012.13, ISSN 0969-7128, pages 102 - 111, XP055608178 [A] 1-16 * abstract *

DOI:   http://dx.doi.org/10.1038/gt.2012.13
 [A]  - WANG WEIJIA ET AL, "Attenuate Newcastle disease virus by codon modification of the glycoproteins and phosphoprotein genes", VIROLOGY, (20190105), vol. 528, doi:10.1016/J.VIROL.2018.12.017, ISSN 0042-6822, pages 144 - 151, XP085613956 [A] 1-16 * abstract *

DOI:   http://dx.doi.org/10.1016/j.virol.2018.12.017
 [A]  - NIU ZESHAN ET AL, "Recombinant Newcastle Disease virus Expressing IL15 Demonstrates Promising Antitumor Efficiency in Melanoma Model", TECHNOLOGY IN CANCER RESEARCH AND TREATMENT, ADENINE PRESS, SCHENECTADY, NY, US, (20150930), vol. 14, no. 5, doi:10.7785/TCRT.2012.500414, ISSN 1533-0346, pages 607 - 615, XP009506737 [A] 1-16 * abstract *

DOI:   http://dx.doi.org/10.7785/tcrt.2012.500414
 [AD]  - DMITRIY ZAMARIN ET AL, "Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions", FUTURE MICROBIOLOGY, GB, (20120301), vol. 7, no. 3, doi:10.2217/fmb.12.4, ISSN 1746-0913, pages 347 - 367, XP055546165 [AD] 1-16 * figure 2 *

DOI:   http://dx.doi.org/10.2217/fmb.12.4
by applicant   - SCHIRRMACHER, "Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance", Expert Opin. Biol. Ther., (20150000), vol. 15, no. 17, pages 57 - 71
    - CASSEL et al., Cancer, (19650000), vol. 1, pages 863 - 888
    - STEINER et al., J. Clin. Oncol., (20040000), vol. 22, pages 4272 - 4281
    - SCHULZE et al., Cancer Immunol. Immunother., (20090000), vol. 58, pages 61 - 69
    - CSATARY et al., Anticancer Res., (19990000), vol. 19, pages 635 - 638
    - PECORA et al., J. Clin. Oncol., (20020000), vol. 20, pages 2251 - 2266
    - LORENCE et al., Curr. Opin. Mol. Ther., (20030000), vol. 5, pages 618 - 624
    - FREEMAN et al., Mol. Ther., (20060000), vol. 13, pages 221 - 228
    - CSATARY LK et al., J Neurooncol., (20040300), vol. 67, no. 1-2, pages 83 - 93
    - CSATARY LK et al., Cancer detection and Prevention, (19930000), vol. 17, no. 6, pages 619 - 627
    - ZAMARINPALESE, Future Microbiol., (20120300), vol. 7, no. 3, pages 347 - 367
    - "Paramyxoviridae: the viruses and their replication", LAMB R, Fields Virology, Lippincott Williams & Wilkins, (20070000), pages 1449 - 1496
    - PEETERS et al., J. Virol., (19990000), vol. 73, pages 5001 - 5009
    - MEBATSION T et al., J Virol., (20021000), vol. 76, no. 20, pages 10138 - 46
    - HUANG et al., J Virol., (20030000), vol. 77, pages 9522 - 9532
    - MEBATSION et al., J Virol., (20010000), vol. 75, pages 420 - 428
    - QIU et al., PLoS ONE, (20160000), vol. 11, no. 2, page e0148560
    - ELANKUMARAN et al., J Virol., (20100000), vol. 84, pages 10113 - 10120
    - JANG et al., Appl Microbiol Biotechnol., (20100000), vol. 85, pages 1509 - 1520
    - ALAMARES et al., Virus Res., (20100000), vol. 147, pages 153 - 157
    - ROUTSAMAL, J Virol., (20080000), vol. 82, pages 7828 - 7836
    - ROMER-OBERDORFER et al., Avian Dis., (20060000), vol. 50, pages 259 - 263
    - PALDURAI et al., J Virol., (20140000), vol. 88, pages 8579 - 8596
    - VIGIL et al., Cancer Res., (20070000), vol. 67, pages 8285 - 8292
    - JANKE et al., Gene Ther., (20070000), vol. 14, pages 1639 - 1649
    - ALTOMONTE et al., Mol Ther., (20100000), vol. 18, pages 275 - 84
    - FITCHET, Proc. Natl. Acad. Sci. USA, (19830000), vol. 80, pages 1382 - 1386
    - NEEDLEMAN et al., J. Mol. Biol., (19700000), vol. 48, pages 443 - 453
    - PEARSONLIPMAN, Proc. Natl Acad. Sci. USA, (19880000), vol. 85, page 2444
    - DORTMANS et al., J. Gen. Virol., (20090000), vol. 90, pages 2746 - 589
    - DE LEEUW et al., J. Gen. Virol., (20050000), vol. 86, pages 1759 - 69
    - BLACH-OLSZEWSKA et al., "Why HeLa cells do not produce interferon?", Arch Immunol Ther Exp (Warsz, (19770000), vol. 25, pages 683 - 91
    - CHNG et al., "Cleavage efficient 2A peptides for high level monoclonal antibody expression in CHO cells", mAbs, vol. 7, no. 2, (20150000), pages 403 - 412, URL: http://dx.doi.org/10.1080/19420862.2015.1008351
    - ENOCH et al., "Activation of the Human beta-Interferon Gene Requires an Interferon-Inducible Factor", Mol. Cell. Biol., (19860000), vol. 6, pages 801 - 10
    - HARYADI et al., "Optimization of Heavy Chain and Light Chain Signal Peptides for High Level Expression of Therapeutic Antibodies in CHO Cells", PLoS ONE, (20150000), vol. 10, no. 2, doi:doi:10.1371/journal.pone.0116878, page e0l 16878, XP055238226

DOI:   http://dx.doi.org/10.1371/journal.pone.0116878
    - ZAMARIN et al., "Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy", Sci. Transl. Med., (20140000), vol. 6, no. 226, doi:doi:10.1126/scitranslmed.3008095, XP055296235

DOI:   http://dx.doi.org/10.1126/scitranslmed.3008095
    - ZAMARINPALESE, "Oncolytic Newcastle Disease Virus for cancer therapy: old challenges and new directions", Future Microbiol., (20170000), vol. 7, doi:doi:10.2217/fmb.12.4, pages 347 - 67, XP055546165

DOI:   http://dx.doi.org/10.2217/fmb.12.4
 EP20180166400
 EP20190154204
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.